

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 1/5/1979  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Early and Established Rheumatoid Arthritis (RA) Panel**

ARUP test code 3017891

Rheumatoid Factor <10 IU/mL (Ref Interval: 0-14)

Cyclic Citrullinated Peptide Ab, IgG/A 5 Units (Ref Interval: 0-19)  
INTERPRETIVE INFORMATION: Cyclic Citrullinated Peptide Ab, IgG/A

19 Units or less ..... Negative  
20-39 Units ..... Weak Positive  
40-59 Units ..... Moderate Positive  
60 Units or greater ..... Strong Positive

A positive result for cyclic citrullinated peptide (CCP) antibodies in conjunction with consistent clinical features may be suggestive of rheumatoid arthritis (RA). Anti-CCP, IgG/IgA antibodies are present in about 66-74 percent of RA patients and have specificities of 96-99 percent. Detection of IgA antibodies in addition to the usual IgG antibodies enhances the sensitivity due to some RA patients having IgA antibodies to CCP in the absence of IgG. These autoantibodies may be present in the preclinical phase of disease, are associated with future RA development, and may predict radiographic joint destruction. Patients with weak positive results should be monitored and testing repeated.

14-3-3 eta Protein, Serum <0.20 ng/mL (Ref Interval: <=0.19)  
INTERPRETIVE INFORMATION: 14-3-3 eta Protein by ELISA, Serum

The combination of serum 14-3-3 eta with rheumatoid factor (RF) and anticyclic citrullinated peptide (anti-CCP) may enhance sensitivity and demonstrates high specificity for rheumatoid arthritis (RA) diagnosis. Elevated serum 14-3-3 eta levels may be observed in both early and established RA patients, including those who are seronegative for both RF and anti-CCP antibodies. Elevated serum 14-3-3 eta concentrations are predictive of unfavorable clinical and radiological outcomes at diagnosis and posttreatment initiation. Negative or decreased levels of 14-3-3 eta from baseline correlate with diminished radiological progression and suboptimal treatment response.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Rheumatoid Factor	24-299-402484	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Cyclic Citrullinated Peptide Ab, IgG/A	24-299-402484	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
14-3-3 eta Protein, Serum	24-299-402484	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 24-299-402484  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 2 of 2 | Printed: 11/5/2024 9:41:17 AM  
4848